Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2010-12-17 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir flyttas till NASDAX OMX Stockholm Mid Cap
Regulatory Filings Classification · 95% confidence The document is a press release dated December 17, 2010, announcing that Medivir AB is being moved from the Small Cap list to the Mid Cap list on NASDAX OMX Stockholm, effective January 3, 2011. This announcement concerns a change in the company's listing status, which relates to its capital structure and market presence. While it is a general announcement, it is not a standard regulatory filing like 10-K, ER, or IR. It is a specific corporate action announcement. Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate fit as a change in market listing tier is fundamentally related to capital structure/market positioning. It is not a Director's Dealing (DIRS), Dividend (DIV), or Share Issue (SHA). Since it is a specific corporate announcement about market tier change, CAP is preferred over the general fallback RNS.
2010-12-17 Swedish
Declaration of Voting Results & Voting Rights Announcements 2010
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Länsförsäkringar Fondförvaltning AB) in the issuer (Medivir Aktiebolag). It explicitly states the 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights dropping below a threshold (implied by the 5% limit mentioned). This structure perfectly matches the definition of a Major Shareholding Notification.
2010-12-14 English
Major Shareholding Notification 2010
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for 'Skandia Fonder AB' concerning 'Medivir Aktiebolag'. It explicitly mentions 'Reason for major shareholding notification' and provides 'Before the transaction' and 'After the transaction' figures, including percentages of shares and voting rights. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2010-12-10 English
Medivir’s U.S. commercialisation partner Meda presents positive Xerese™ data at ASHP
Investor Presentation Classification · 92% confidence The document is a press release dated December 8, 2010, announcing that Medivir's US commercialization partner, Meda, presented positive Phase 3 data for the cold sore treatment Xerese™ at a medical conference (ASHP). It details study results, product information, indications, and risk information. This is not a formal regulatory filing like a 10-K, nor is it a transcript of an earnings call (CT). It is an announcement of clinical/product data dissemination, which fits best under the general category of Investor Relations or a specific product update. Since there is no specific code for 'Clinical Data Presentation Announcement,' and it is a formal announcement intended for investors and the public regarding product progress, it is most appropriately classified as an Investor Presentation (IP) if it were a slide deck, or more generally, a Regulatory Filing (RNS) if it doesn't fit other specific categories. However, given the content is a detailed summary of clinical trial results and product facts, it functions similarly to an Investor Presentation (IP) or a general announcement. Since it is a press release detailing scientific/product progress rather than a formal financial report or a management change, RNS (Regulatory Filings/General Announcement) is the safest fallback, but IP (Investor Presentation) often covers detailed product/pipeline updates shared with investors. Given the context of presenting data, IP is a strong candidate, but RNS covers general announcements well. Let's re-evaluate the definitions. It is not a DEF 14A (Remuneration), 10-K (Annual Report), or ER (Earnings Release). It is a detailed update on a product's clinical trial results presented at a meeting. This type of announcement often falls under Investor Presentation (IP) materials, even if presented as a press release, as it is strategic information for investors. I will classify it as IP due to the detailed scientific/product focus, which is typical of investor presentations.
2010-12-08 English
Medivirs försäljningspartner i USA, Meda, presenterar positiva resultat för Xerese™ vid ASHP:s konferens
Regulatory Filings Classification · 97% confidence The document is a press release dated December 8, 2010, announcing that Medivir's US sales partner, Meda, presented positive virology results for the drug Xerese™/Xerclear® at the ASHP conference. The text details the study results, drug indication, important risk information, and contact details for Medivir and its PR agency. This type of announcement, focusing on the presentation of clinical data or study results outside of a formal quarterly/annual filing, is best classified as a general announcement or a specific type of investor communication. Since it is a press release detailing scientific/clinical updates and product information, it is not a formal regulatory filing like 10-K or IR. It is not a Call Transcript (CT), Earnings Release (ER), or a formal Investor Presentation (IP). Given the content is a specific announcement about clinical data presentation, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate/scientific update, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Since it is a press release announcing data, RNS is the most appropriate fallback for non-standard announcements, although it contains significant product information. Given the context of presenting study results, it is a form of investor/scientific communication. However, it is structured as a standard press release announcing an event/data presentation, making RNS the most suitable general regulatory announcement category when a more specific one (like ER or IR) doesn't apply to the *nature* of the announcement itself.
2010-12-08 Swedish
Villkoren för Medivirs riktade nyemission nu uppfyllda
Capital/Financing Update Classification · 98% confidence The document is a press release dated December 6, 2010, titled "Villkoren för Medivirs riktade nyemission nu uppfyllda" (The terms for Medivir's directed new share issue have now been met). It explicitly discusses the decision to issue 2,250,000 new B shares at 125 SEK per share, the fulfillment of the terms, and the subsequent trading date. This content directly relates to fundraising, financing activities, and changes in capital structure (a directed new share issue or private placement). This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it is a press release, the core subject matter is the financing event itself, not just an announcement of a report's publication (RPA/RNS).
2010-12-06 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.